CMS demo could pave the path to eliminating Part D rebates

The Trump administration is laying the groundwork to put policies in place in 2020 that would reduce out-of-pocket spending by senior citizens with high drug costs, boost drug company revenues -- and shift undetermined costs to taxpayers.

In a memo released April 5, CMS signaled its intention to shield drug plans from uncertainty associated with the agency’s proposal to scrap rebates drug companies pay to secure Medicare

Read the full 668 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE